Genotype and Susceptibility to COVID-19

Active, not recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

September 20, 2021

Study Completion Date

June 30, 2024

Conditions
Covid19
Interventions
OTHER

Questionnaire administration,blood sampling and genetic analyses.

"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."

Trial Locations (1)

24020

"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER